Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

741. Maternal iron deficiency and the risk of schizophrenia in offspring Full Text available with Trip Pro

Maternal iron deficiency and the risk of schizophrenia in offspring Iron is essential for brain development and functioning. Emerging evidence suggests that iron deficiency in early life leads to long-lasting neural and behavioral deficits in infants and children. Adopting a life course perspective, we examined the effects of early iron deficiency on the risk of schizophrenia in adulthood.To determine whether maternal iron deficiency, assessed by maternal hemoglobin concentration during (...) pregnancy, increases the susceptibility to schizophrenia spectrum disorders (SSDs) among offspring.Data were drawn from a population-based cohort born from 1959 through 1967 and followed up for development of SSD from 1981 through 1997.Of 6872 offspring for whom maternal hemoglobin concentration was available, 57 had SSDs (0.8%) and 6815 did not (99.2%).Prospectively assayed, the mean value of maternal hemoglobin concentration was the primary exposure. Hemoglobin concentration was analyzed

2008 EvidenceUpdates

742. Schizophrenia and offspring`s risk for adverse pregnancy outcomes and infant death Full Text available with Trip Pro

Schizophrenia and offspring`s risk for adverse pregnancy outcomes and infant death Women with schizophrenia are at increased risk for adverse pregnancy outcomes. It is not known whether offspring born to fathers with schizophrenia also have an increased risk.To evaluate paternal and maternal influences on the association between schizophrenia and pregnancy outcomes.A record linkage including 2 million births was made using Swedish population-based registers. The risk for adverse pregnancy (...) outcomes was evaluated through logistic regression.Offspring with a mother or father with schizophrenia faced a doubled risk of infant mortality, which could not be explained by maternal behaviour alone during pregnancy. Excess infant death risk was largely attributable to post-neonatal death. Maternal factors (e.g. smoking) explained most of the other risks of adverse pregnancy outcomes among both mothers and fathers with schizophrenia.The risks to offspring whose fathers had schizophrenia suggest

2008 EvidenceUpdates

743. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. (Abstract)

Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental disorders. People in a catatonic state have increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug therapies and electroconvulsive therapy.To compare the effects of benzodiazepines with other drugs, placebo (...) or electroconvulsive therapy for people with catatonia.We searched the Cochrane Schizophrenia Group Trials Register (March 2007) and manually searched reference lists from the selected studies.All relevant randomised controlled clinical trials.We (RCG, GW) extracted data independently. For dichotomous data we would have calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis using a fixed-effect model.No studies could be included. We did find studies reporting

2008 Cochrane

744. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering (Abstract)

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering Although recent treatment guidelines for schizophrenia recommend that the prior antipsychotic agent should remain stable for at least 2 weeks when aripiprazole is introduced, there is no trial-based evidence to support this strategy. This study was designed to compare this strategy (...) with another conventional one in patients with schizophrenia. We conducted a randomized, 14-week, open-label trial to compare the following 2 switching strategies: (1) add-on of aripiprazole on a current regimen, wait for 4 weeks, and the tapering of prior antipsychotics and (2) add-on of aripiprazole and the simultaneous tapering of prior antipsychotics in patients with schizophrenia. Aripiprazole was initiated at 12 mg/d and then titrated between 12 and 30 mg. The previous antipsychotic medication

2008 EvidenceUpdates Controlled trial quality: uncertain

745. Initial phase 2 trial of a nicotinic agonist in schizophrenia Full Text available with Trip Pro

Initial phase 2 trial of a nicotinic agonist in schizophrenia Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of alpha(7)-nicotinic receptors. Patients' heavy smoking suggests attempted self-medication through this mechanism. The agent 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A) is a partial alpha(7)-nicotinic agonist and can be taken orally. A phase 1 trial showed (...) evidence for cognitive enhancement in schizophrenia.Thirty-one subjects with schizophrenia received DMXB-A at two different doses and placebo for periods of 4 weeks in a three-arm, two-site, double-blind, crossover phase 2 trial. The MATRICS Consensus Cognitive Battery assessed cognitive effects, and the Scale for the Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Scale (BPRS) assessed clinical effects. Subjects continued their current antipsychotic drug during the trial and were

2008 EvidenceUpdates Controlled trial quality: uncertain

746. Music therapy improves symptoms in adults hospitalised with schizophrenia

Music therapy improves symptoms in adults hospitalised with schizophrenia Music therapy improves symptoms in adults hospitalised with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Music therapy improves symptoms in adults hospitalised with schizophrenia Article Text Therapeutics Music therapy improves symptoms in adults hospitalised with schizophrenia Statistics from Altmetric.com Request Permissions If you wish to reuse

2008 Evidence-Based Mental Health

747. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) and ziprasidone in acute schizophrenia Article Text Therapeutics Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways

2008 Evidence-Based Mental Health

748. Adherence therapy does not improve quality of life in people with schizophrenia

Adherence therapy does not improve quality of life in people with schizophrenia Adherence therapy does not improve quality of life in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adherence therapy does not improve quality of life in people with schizophrenia Article Text Therapeutics Adherence therapy does not improve quality of life in people with schizophrenia Statistics from Altmetric.com Request

2008 Evidence-Based Mental Health

749. Predictors of symptomatic remission in people with schizophrenia identified

Predictors of symptomatic remission in people with schizophrenia identified Predictors of symptomatic remission in people with schizophrenia identified | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Predictors of symptomatic remission in people with schizophrenia identified Article Text Prognosis Predictors of symptomatic remission in people with schizophrenia identified Statistics from Altmetric.com Request Permissions If you wish

2008 Evidence-Based Mental Health

750. Ziprasidone hydrochloride - Schizophrenia and related psychotic disorders

Ziprasidone hydrochloride - Schizophrenia and related psychotic disorders Common Drug Review CEDAC Meeting – July 16, 2008 Page 1 of 2 Notice of CEDAC Final Recommendation – August 14, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ZIPRASIDONE HYDROCHLORIDE (Zeldox ™ – Pfizer Canada Inc.) Description: Ziprasidone is an antipsychotic agent that is approved for the treatment of schizophrenia and related psychotic disorders. Dosage Forms: 20 mg, 40 mg, 60 mg and 80 mg (...) capsules. The recommended dose ranges from 20 mg to 80 mg given twice daily. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that ziprasidone be listed for the treatment of schizophrenia and schizoaffective disorders in patients who have failed a trial of less expensive antipsychotic agents due to a contraindication, intolerance or lack of response. Reasons for the Recommendation: 1. Randomized controlled trials (RCTs) have demonstrated that ziprasidone is generally

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

751. Head injury slightly increases risk of non-affective psychosis but not schizophrenia

Head injury slightly increases risk of non-affective psychosis but not schizophrenia Head injury slightly increases risk of non-affective psychosis but not schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Head injury slightly increases risk of non-affective psychosis but not schizophrenia Article Text Aetiology Head injury slightly increases risk of non-affective psychosis but not schizophrenia Statistics from

2008 Evidence-Based Mental Health

752. Cannabis and schizophrenia. Full Text available with Trip Pro

Cannabis and schizophrenia. Many people with schizophrenia use cannabis and its effects on the illness are unclear.To evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses.We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO.We included all randomised trials involving cannabinoids and people with schizophrenia or schizophrenia-like (...) , there is insufficient evidence to support or refute the use of cannabis/cannabinoid compounds for people suffering with schizophrenia. This review highlights the need for well designed, conducted and reported clinical trials to address the potential effects of cannabis based compounds for people with schizophrenia.

2008 Cochrane

753. Aripiprazole versus typical antipsychotic drugs for schizophrenia. (Abstract)

Aripiprazole versus typical antipsychotic drugs for schizophrenia. Aripiprazole is a relatively new antipsychotic drug, said to be the prototype of a new third generation of antipsychotics; the so-called dopamine-serotonin system stabilisers. In this review we examine how the efficacy and tolerability of aripiprazole differs from that of typical antipsychotics.To evaluate the effects of aripiprazole compared with other typical antipsychotics for people with schizophrenia and schizophrenia-like (...) psychoses.We searched the Cochrane Schizophrenia Group Trials Register (November 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.We included all randomised trials comparing aripiprazole with typical antipsychotics in people with schizophrenia or schizophrenia-like

2008 Cochrane

754. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia (Abstract)

A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation. Empirical evidence has shown that some herbal medicines have suppressive effects on prolactin (PRL) hyperactivities. This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (...) %). Moreover, there was a significantly greater proportion of patients during PGD treatment than BMT treatment showing improvements on adverse effects associated with hyperprolactinemia (56% vs 17%, P = 0.037). These results suggest that the herbal therapy can yield additional benefits while having comparable efficacy in treating antipsychotic-induced hyperprolactinemia in individuals with schizophrenia.

2008 EvidenceUpdates Controlled trial quality: uncertain

755. A meta-analysis of controlled research on social skills training for schizophrenia Full Text available with Trip Pro

A meta-analysis of controlled research on social skills training for schizophrenia A meta-analysis of randomized, controlled trials of social skills training for schizophrenia was conducted. Outcome measures from 22 studies including 1,521 clients were categorized according to a proximal-distal continuum in relation to the presumed site of action of skills training interventions, with content mastery tests and performance-based measures of skills assumed to be most proximal, community (...) skills training for improving psychosocial functioning in schizophrenia.(c) 2008 APA, all rights reserved

2008 EvidenceUpdates

756. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis Full Text available with Trip Pro

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis The increased prevalence of diabetes in schizophrenia is partly attributed to antipsychotic treatment, in particular second-generation antipsychotics, but the evidence has not been systematically reviewed.Systematic review and meta-analysis comparing diabetes risk for different antipsychotics in people with schizophrenia.We searched MEDLINE, PsycINFO, EMBASE, International (...) Pharmaceutical Abstracts, CINAHL and Web of Knowledge until September 2006. Studies were eligible for inclusion if the design was cross-sectional, case-control, cohort or a controlled trial in individuals with schizophrenia or related psychotic disorders, where second-generation antipsychotics (defined as clozapine, olanzapine, risperidone and quetiapine) were compared with first-generation antipsychotics and diabetes was an outcome. Data were pooled using random effects inverse variance weighted meta

2008 EvidenceUpdates

757. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review Full Text available with Trip Pro

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia.English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder (...) or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial. Randomized, double-blind, placebo-controlled, monotherapy studies with comparable doses in both BPD and schizophrenia were included. Absolute risk increase and number needed to treat to harm (NNTH) for akathisia, overall EPS, and anticholinergic use relative to placebo were estimated.Eleven trials in mania, 4

2008 EvidenceUpdates

758. Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia

Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) -generation antipsychotics in people with treatment resistant schizophrenia Article Text Therapeutics Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant

2008 Evidence-Based Mental Health

759. Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia Full Text available with Trip Pro

Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia Article Text Therapeutics Brief

2008 Evidence-Based Mental Health

760. Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Article Text Therapeutics Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Statistics from

2008 Evidence-Based Mental Health